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Glucocorticoids (GCs) are commonly used for 
therapy of various hematologic malignancies, 
most notably acute lymphoblastic leukemia, 
multiple myeloma, and chronic lymphocytic 
leukemia (1, 2). The eff  ectiveness of this ap-
proach is based on the ability of GCs to induce 
apoptosis of leukemic cells. Yet, the mecha-
nisms by which GC causes apoptosis remain 
obscure (2, 3).
Apoptosis by GC requires its binding to the 
glucocorticoid receptor (GR). Several GR iso-
forms have been identifi  ed (4), the GRα iso-
form being the predominant active form. The 
GR protein contains two transactivation do-
mains, a zinc-fi   nger DNA-binding domain 
(DBD) and a ligand-binding domain (LBD) (5, 
6). The DBD consists of two highly conserved 
zinc fi  ngers, which are crucial for the binding 
to glucocorticoid response element (GRE) se-
quences. In addition, the fi  rst  zinc-fi  nger  of 
DBD binds NFκB and AP-1 (7, 8), and the 
second DBD zinc fi  nger mediates receptor di-
merization (9). The LBD binds GC as well as 
heat-shock proteins (10) and is also involved in 
receptor dimerization (6).
Numerous studies indicate that in the ab-
sence of a ligand, GR is sequestered in the cy-
tosol bound to a large heteromeric complex of 
heat-shock proteins and immunophilins (10) 
or to 14–3-3σ (11). Upon ligand-binding, GR 
translocates to the nucleus where it transactivates 
and transrepresses multiple genes (3, 5). Transac-
tivation occurs through interaction with GREs, 
whereas transrepression follows binding and in-
activation of AP-1 and NFκB. It is unknown 
which of these alterations in gene expression are 
essential for the apoptotic eff  ect of GC.
Some diff  erences have been observed in the 
spectrum of genes aff  ected by GC in GC-sensi-
tive versus GC-resistant cells (12). Of note are 
the up-regulation of the pro-apoptotic gene 
Bim in GC-sensitive cells (13) and the down-
regulation of the survival gene c-Myc (3). It 
has been suggested that the many eff  ects of GC 
may shift the balance between prosurvival and 
proapoptotic factors, ultimately leading to cell 
death (2, 3). As AP-1 and NFκB control sev-
eral survival pathways, the interaction of GR 
with these factors is believed to play a major 
role in GC-mediated apoptosis (3, 5). This no-
tion is supported by the observation that a GR 
mutant (GR-LS7) compromised in transactiva-
tion, but normal in transrepression, is as eff  ec-
tive as the WT receptor in inducing apoptosis 
(14). However, a dimerization-defective GR 
is unable to mediate GC-induced apoptosis, 
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  although it causes transrepression through interaction with 
AP-1 and NFκB (9). Thus, interference with AP-1 and NFκB 
functions per se is insuffi   cient for inducing apoptosis. The 
role of transrepression is further questioned by the study of 
Tao et al. (7), who showed that a GR mutant defi  cient in 
transrepression is still able to induce apoptosis. Because di-
merization is required for DNA binding (9), it was suggested 
that DNA binding is a prerequisite for eliciting the apoptotic 
response. However, a DNA-binding defective variant of GR, 
which is mainly localized in the cytosol, still induces apoptosis 
(15). These data suggest that GC may induce apoptosis by a 
yet unknown pathway, which is independent of the nuclear 
eff  ects of GR.
Although GR is predominantly cytosolic, a plasma mem-
brane form of GR (mGR) has been detected in some lym-
phoid cells (16, 17). Expression of mGR was found to be 
associated with GR mRNA transcript 1A (18), which is one 
of several GR transcripts expressed most abundantly in he-
matopoietic cell lines sensitive to GC-induced apoptosis (19, 
20). It was thus suggested that mGR may be responsible for 
GC-induced apoptosis. Other studies, however, did not show 
correlation between expression of mGR and sensitivity to 
GC (2).
Several reports have shown that GR translocates to the mi-
tochondria in addition to its well-characterized nuclear trans-
location (21–24). As GC-induced apoptosis is mediated via 
the mitochondrial pathway (2), we addressed the question 
whether GR translocation to the mitochondria is essential for 
GC-induced apoptosis. We found correlation between mito-
chondrial GR translocation and sensitivity of cells to GC-in-
duced apoptosis. Moreover, a GR variant that is exclusively 
expressed in the mitochondria enabled apoptosis of various 
cancer cell lines. Altogether, our data indicate a role for mi-
tochondrial GR in eliciting apoptosis.
RESULTS
GC-sensitive PD1.6 and 2B4 cells do not express plasma 
membrane GR
We used a series of lymphoma and leukemia cells to study the 
mechanisms of GC-induced apoptosis. Susceptibility to GC-
induced apoptosis was determined by appearance of subdip-
loid cells and caspase 3 activation. PD1.6 and 2B4 cells readily 
apoptose in response to GC, whereas B10, S49, NB4, and 
Jurkat cells are resistant to GC-induced apoptosis (Fig. 1, A–
C). It should be noted that the S49 variant used in this study 
(25) diff  ers from the S49 variant described by Gametchu et al. 
(16) in being resistant to GC-induced apoptosis. Because it 
has been proposed that mGR is a mediator of GC-induced 
apoptosis (18), we compared mGR expression on GC-sensi-
tive and resistant cells. It appears that S49, but not PD1.6, 
B10, 2B4, or Jurkat cells, express mGR (Fig. 1 D, subpanels 
A vs. C, E, G, and I, respectively). Also, the macrophage cell 
line RAW264.7 expresses a high level of mGR and is resis-
tant to GC-induced apoptosis (unpublished data). Treatment 
with 100 nM dexamethasone (Dex) for 2 h did not induce ex-
pression of mGR on otherwise mGR-negative cells (Fig. 1 D, 
Figure 1.  (A) Sensitivity of various lymphoma and leukemia cell 
lines to Dex-induced apoptosis. Cells were incubated with 100 nM Dex 
for 20 h, and the DNA content measured by fl  ow cytometry using prop-
idium iodide. Percentage of subdiploid cells is given. (B) Dose–response to 
Dex. Cells were incubated with various concentrations of Dex and pro-
cessed as in A. (C) Caspase 3 activation. Untreated or Dex-treated cells 
were stained for activated caspase 3 as described in Materials and meth-
ods. Percentage of positive cells is given. (D) Expression of mGR on lym-
phoma and leukemia cells. Untreated cells or cells treated with 100 nM 
Dex for 2 h were incubated with M20 antibodies to GR and FITC-conju-
gated goat anti–rabbit IgG (dashed line) or FITC-conjugated goat anti–
rabbit IgG only (solid line). The fl  uorescence intensity was measured by 
fl  ow cytometry.JEM VOL. 203, January 23, 2006  191
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subpanels D, F, H, and J). The fact that GC-resistant S49 and 
RAW264.7 cells express mGR indicates that expression of 
mGR per se does not impose susceptibility to GC. The ob-
servation that GC-sensitive PD1.6 and 2B4 cells do not ex-
press mGR suggests that another mechanism is involved in 
this apoptotic process.
Translocation of GR to the mitochondria and sensitivity to 
GC-induced apoptosis
It has recently been shown that GR may be localized to the 
mitochondria (24). As GC-evoked apoptosis is mediated via 
the mitochondrial pathway (2), we asked whether GR trans-
location to the mitochondria may be a trigger of apoptosis. 
To answer this question, we analyzed the intracellular traf-
fi  cking of GR in GC-sensitive and resistant cells after treat-
ment with Dex. Dex-induced GR translocation to the 
mitochondria was demonstrated in GC-sensitive PD1.6 cells 
using two diff  erent methods (Fig. 2, A, B, and E). First, im-
munofl  uorescence studies using M20 antibodies to GR and 
red mitotracker to visualize the mitochondria show that a 
certain fraction of GR localizes to the mitochondria in Dex-
treated PD1.6 cells (Fig. 2 A). Second, PD1.6 cells treated 
with 100 nM Dex for 2 h were fractionated using the Onco-
gene cytosol/mitochondria fractionation kit. The quantities 
of GR in the cytosolic and mitochondrial fractions were ana-
lyzed by Western blotting (Fig. 2 B). The PA1-511A anti-
body to GR (epitope aa 346–367) resolves two major bands 
on Western blots. The top one is GRα, whereas the bottom 
band is of unknown character and considered in Fig. 2 as a 
“background band.” GR expression in the mitochondrial 
Figure 2.  (A) Intracellular staining of GR. PD1.6 cells were treated 
with 100 nM Dex for 2 h and the mitochondria were stained with 50 nM 
mitotracker. Rehydrated methanol-fi  xed cells were incubated with M20 
antibodies to GR and FITC-conjugated goat anti–rabbit IgG, and visualized 
under confocal microscope. Five different cells are presented. (B) Dex in-
duces mitochondrial translocation of GR in PD1.6, but not in PD1.6TEC− 
cells. PD1.6 cells were incubated in the absence or presence of 100 nM 
Dex for 2 h before subcellular fractionation using the Oncogene fraction-
ation kit. GR was detected by Western blotting using the PA1-511A anti-
body to GR (A, C, and D). (C and D) Data were obtained by two different 
exposure times. The blots were reprobed with antibodies to α-tubulin 
(B) and CytoC (D). CytoC could be used as a mitochondrial marker because 
the cells were harvested before any CytoC release. (C) Sensitivity of PD1.6 
and PD1.6TEC− cells to Dex-induced apoptosis. Cells were either untreated 
or treated with 100 nM Dex for 20 h, and percentage of apoptotic cells 
was determined as in Fig. 1 A. (D) The mitochondrial fraction is not con-
taminated by cytosolic or nuclear proteins. Subcellular fractions were run 
side by side on the same gel and analyzed by Western blotting using anti-
bodies to α-tubulin (A), histone 2B (B), and VDAC (C), which react with 
cytosolic, nuclear, and mitochondrial fractions, respectively. (E) Dex in-
duces a rapid, temperature-dependent translocation of GR to the nucleus 
and mitochondria in PD1.6 cells. PD1.6 cells were incubated in the absence 
or presence of 100 nM Dex for 5 and 15 min at 37°C (lanes 1–3) or 4°C 
(lanes 4–6) before subcellular fractionation as described in Materials and 
methods. GR was detected by Western blotting using the PA1-511A anti-
body to GR (A, C, and E). The blots were reprobed with antibodies to 
α-tubulin (B), histone H2B (D), and VDAC (F). (F) Dex induces sustained GR 
translocation to the nucleus and the mitochondria in PD1.6 cells. PD1.6 
cells were incubated in the absence or presence of 100 nM Dex for 30 min 
to 5 h and processed as in E. (G) The mitochondrial GR is also immunore-
active to the M20 and P20 antibodies to GR. The mitochondrial samples 1 and 
2 of F were rerun on gel and probed with either M20 or P20 antibodies.192  MITOCHONDRIAL GLUCOCORTICOID RECEPTOR AND APOPTOSIS | Sionov et al.
fraction of PD1.6 cells is increased after Dex treatment (Fig. 
2 B, subpanels C and D, lane 2 vs. lane 1), indicating mito-
chondrial translocation of GR. Contamination of the mito-
chondrial fraction with mGR is excluded, because PD1.6 
cells do not express mGR even after Dex treatment (Fig. 1 D, 
subpanels C and D). As expected, the amount of GR in the 
cytosolic fraction is reduced by Dex (Fig. 2 B, subpanel A, 
lane 2 vs. lane 1). We also determined the GR expression in 
cytosolic and mitochondrial extracts of PD1.6TEC− cells 
that display reduced sensitivity to Dex-induced apoptosis 
(Fig. 2 C). In contrast with the GC-sensitive parental PD1.6 
cells, the GR level was not increased in the mitochondrial 
fraction of PD1.6TEC− cells treated with Dex (Fig. 2 B, sub-
panels C and D, lane 4 vs. lane 3). These data indicate that 
selection of PD1.6 cells toward apoptotic resistance in re-
sponse to Dex is accompanied with reduced mitochondrial 
translocation of GR.
Because the Oncogene kit does not yield nuclear extracts, 
we applied a cellular fractionation protocol that enabled 
comparison between mitochondrial and nuclear transloca-
tions of GR. Cross-contamination between the cytosolic, 
nuclear, and mitochondrial fractions was ruled out by using 
antibodies against α-tubulin, histone H2B, and VDAC, re-
spectively (Fig. 2 D). As with the Oncogene kit, this method 
detected mitochondrial translocation of GR in Dex-treated 
PD1.6 cells (Fig. 2 E, subpanel E, lanes 2–3 vs. lane 1). A 
longitudinal follow-up (Fig. 2, E and F) revealed mitochon-
drial translocation of GR as early as 5 min after addition of 
Dex, long before the onset of apoptosis. Thereafter, the mi-
tochondrial GR level did not increase further with time 
Figure 3.  (A–E) Dex induces GR translocation to the mitochondria 
in GC-sensitive PD1.6 cells (A), 2B4 cells (B), and thymocytes 
(C), but not in GC-resistant B10 (A), NB4 (D), S49 (E), and Jurkat 
(E) cells. Cells were incubated in the absence or presence of various 
Dex concentrations for 4 h before subcellular fractionation and 
Western blotting. In addition, NB4 cells were treated with 1 μM As2O3 
(D, lanes 5 and 6), which is known to stabilize PML in these cells 
(reference 26).JEM VOL. 203, January 23, 2006  193
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(Fig. 2 E [subpanel E, compare lanes 2 and 3] and F [subpanel 
E, compare lanes 2–5]). Also, the amount of nuclear GR al-
ready peaked at 5 min (Fig. 2, E and F, subpanel C). Similar 
results were obtained with PD1.6 cells treated with the natu-
rally occurring GC corticosterone (unpublished data). The 
mitochondrial GR could also be detected on Western blot 
using the NH2-terminal (aa 5–20)-reacting M20 and the 
COOH-  terminal (aa 750–769)-reacting P20 antibodies (Fig. 
2 G), indicating that this GR is in full-length. To exclude the 
possibility of nonspecifi  c GR binding to the mitochondria, 
we studied whether this translocation is temperature sensi-
tive. To this end, PD1.6 cells were exposed to Dex at 4°C for 
5–15 min before subcellular fractionation. GR did not trans-
locate to either the mitochondria or the nucleus at 4°C (Fig. 
2 E, compare lanes 5 and 6 with lanes 2 and 3), indicating 
that the GR mitochondrial localization is specifi  c and tem-
perature dependent.
Next, we compared GR translocation to the mitochon-
dria in GC-sensitive PD1.6 cells and GC-insensitive B10 
cells (Fig. 3 A). PD1.6 and B10 cells are both derived from a 
thymic lymphoma, and express similar GR levels. The cells 
were exposed to 5 and 100 nM Dex for 4 h before subcellular 
fractionation. Dex induced GR translocation to the nucleus 
in both PD1.6 and B10 cells (Fig. 3 A, subpanel C, lanes 2, 
3, 5, and 6). A dose-dependent mitochondrial translocation 
of GR was observed in PD1.6 cells (Fig. 3 A, subpanel E, 
lanes 2 and 3), but not in B10 cells (Fig. 3 A, subpanel E, 
lanes 5 and 6). In some experiments, a slight increase in GR 
expression was seen in mitochondrial extracts of B10 cells 
treated with 100 nM Dex (unpublished data), which refl  ects 
residual sensitivity (10–12%) of these cells to Dex (Fig. 1 B). 
Moreover, Dex induced GR translocation to both the nu-
cleus and the mitochondria in GC-sensitive 2B4 cells (Fig. 3 B) 
and thymocytes (Fig. 3 C). In 2B4 cells, nuclear translocation 
of GR was induced by as low as 1 nM Dex, a nontoxic con-
centration (Fig. 3 B, subpanel C, lane 2). This Dex concen-
tration was insuffi   cient to cause mitochondrial GR translocation 
in the same cells (Fig. 3 B, subpanel E, lane 2). However, at 
toxic Dex concentrations (10 and 100 nM), GR translocated 
to the mitochondria as well (Fig. 3 B, subpanel E, lanes 3 and 
4 vs. lane 1).
Contrary to GC-sensitive cells, GC-resistant NB4 (Fig. 3 D, 
lanes 3–6) and S49 (Fig. 3 E, lanes 1–3) cells responded to 
Dex with GR translocation to the nucleus, but not to the 
mitochondria. We also treated NB4 cells with As2O3, which 
stabilizes PML and degrades the PML–RAR fusion protein 
(26). As2O3 stabilized GR in these cells (Fig. 3 D, subpanel 
A, lane 5 vs. lane 3) to a level comparable with that of PD1.6. 
Even after As2O3 treatment, Dex did not cause mitochon-
drial translocation of GR in NB4 cells (Fig. 3 D, subpanel E, 
lane 6). Although S49 cells express a high basal level of GR 
(Fig. 3 E, subpanel A, lane 1), no GR translocation to the 
mitochondria is seen (Fig. 3 E, subpanel E, lanes 2 and 3). 
Thus, mitochondrial GR translocation does not correlate 
with GR expression but rather with the apoptotic sensitivity 
to GC.
Jurkat cells express a very low level of GR (Fig. 3 E, sub-
panel A, lane 4), which may explain their unresponsiveness 
to the apoptotic eff  ects of GC. It is well documented that 
GC-induced apoptosis requires a threshold level of GR (24, 
27). Although GR translocates to the nucleus in Dex-treated 
Jurkat cells (Fig. 3 E, subpanel C, lanes 5 and 6), GR is barely 
seen in the mitochondria (Fig. 3 E, subpanel E, lanes 5 and 
6). Moreover, Jurkat cells express one WT and one mutated 
(R477H) GR allele, as do the GC-sensitive CCRF–CEM 
cells (28).
It should be noted that in most of the GR-expressing cell 
lines tested, a certain basal level of GR is detected in the mi-
tochondria (e.g., Fig. 3 A [subpanel E, lanes 1 and 4], B [sub-
panel E, lane 1], and E [subpanel E, lane 1]). Altogether, the 
data demonstrate correlation between GR translocation to 
the mitochondria and sensitivity to GC-induced apoptosis.
Mitochondrial translocation of GR can occur without 
concomitant apoptosis
The GR antagonist RU486 induces a diff  erent conforma-
tional change of GR than GC agonists (29). It causes nuclear 
Figure 4.  (A) RU-486 prevents Dex-induced apoptosis of PD1.6 
cells. PD1.6 cells were incubated with various concentrations of Dex in 
the absence or presence of 5 μM RU-486 for 20 h. Percentage of apopto-
sis was determined as in Fig. 1 A. (B) RU-486 induces mitochondrial 
translocation of GR in PD1.6 cells. Cells were incubated in the absence or 
presence of 5 μM RU-486 and/or 100 nM Dex for 2 h followed by subcel-
lular fractionation and Western blotting.194  MITOCHONDRIAL GLUCOCORTICOID RECEPTOR AND APOPTOSIS | Sionov et al.
translocation of GR, but prevents its binding to GREs, thereby 
avoiding transactivation. We sought to fi  nd out whether RU486 
aff  ects mitochondrial translocation of GR. Initially, we ana-
lyzed the eff  ect of RU486 on Dex-induced apoptosis of 
PD1.6 cells. As expected, RU486 prevented this apoptotic 
response (Fig. 4 A). When looking on the intracellular traf-
fi  cking of GR, we found that RU486 induced both nuclear 
and mitochondrial translocation of GR in PD1.6 cells (Fig. 
4 B, subpanel C and E, respectively, lane 3). A combination 
of RU486 and Dex had an additive eff  ect on GR transloca-
tion to the mitochondria (Fig. 4 B, subpanel E, lane 4). These 
data indicate that a mere localization of GR to the mitochon-
dria is insuffi   cient for inducing apoptosis, which apparently 
requires a particular GR conformation.
TEC induces mitochondrial, but not nuclear, translocation 
of GR in PD1.6 cells
We have recently shown that thymic epithelial cells (TECs) 
induce apoptosis of PD1.6 cells in a GR-dependent manner 
(30). It was therefore of interest to study the intracellular traf-
fi  cking of GR in PD1.6 cells cocultured with TECs. For this 
purpose, PD1.6 cells were incubated alone or on a TEC 
monolayer for 4 h. In PD1.6 cells grown alone, most of the 
GR is localized in the cytosol (Fig. 5 A, lane 1). After cocul-
tivation with TECs, GR is found in the mitochondrial frac-
tion, but, surprisingly, not in the nuclear fraction (Fig. 5, 
compare lane 2 in subpanel E vs. subpanel C). PD1.6 cells 
treated with 100 nM Dex for 4 h were used as a positive 
control for nuclear translocation. As expected, this treatment 
caused both nuclear and mitochondrial translocation of GR 
(Fig. 5, lane 7 in subpanels C and E, respectively). Cocultiva-
tion on TEC did not cause a reduction in the cytosolic GR 
level as seen with Dex (Fig. 5 A, compare lanes 2 and 7 with 
lane 1). It should be noted that a similar quantity of GR was 
observed in the mitochondrial fractions of PD1.6 cells 
  cocultivated with TECs and of PD1.6 cells treated with 100 
nM Dex (Fig. 5 E, compare lanes 2 and 7). This outcome is 
consistent with the similar extent of apoptosis induced by 
these two stimuli (30). To exclude the possibility that GR 
detected in PD1.6 cells cocultured with TECs is due to TEC 
contamination, we included in the experiment Dex-resistant 
PD1.6Dex− cells that express minute amount of GR (30). 
No GR could be seen in the mitochondrial or nuclear frac-
tions of these cells after cocultivation with TECs (Fig. 5, lane 
4 in subpanels E and C, respectively). As a negative control, 
we used TEC-resistant PD1.6TEC− cells (30), which show 
only a slight reduction in GR expression level in comparison 
to the parental PD1.6 cells. Interestingly, TECs induced nei-
ther mitochondrial nor nuclear translocation of GR in 
PD1.6TEC− cells (Fig. 5, lane 6 in subpanels E and C, re-
spectively). Altogether, our data demonstrate that TEC in-
duces GR translocation to the mitochondria in TEC-sensitive 
PD1.6 cells, but not in TEC-resistant PD1.6TEC− cells. Be-
cause TEC causes apoptosis of PD1.6 cells in a GR-depen-
dent manner (30) and induces mitochondrial (but not nuclear) 
GR translocation, we propose that GR translocated to the 
mitochondria is a trigger of apoptosis. Our fi  ndings also show 
that the nuclear and mitochondrial translocations of GR are 
diff  erentially regulated.
The mitochondrial localization signal (MLS) and the 
nuclear localization signal (NLS) are located at different 
domains of GR
Our data showing that, depending on circumstances, GR 
translocates either to the nucleus or to the mitochondria, 
suggest that nuclear and mitochondrial GR translocations are 
diff  erentially regulated. We therefore searched for signals di-
recting the intracellular traffi   cking of GR. To this end, we 
transfected GR-negative 293 cells with WT or various dele-
tion mutants of human GR (hGR). In the absence of ligand, 
the transfected GR is expressed in cytosol, nucleus, and mi-
tochondria (Fig. 6 A, lane 1). Addition of Dex did not alter the 
intracellular distribution of GR in these cells (unpublished 
data). This pattern of exogenous GR expression enabled the 
search for NLS and MLS. Using 293 cells transfected with 
GR deletion mutants, we found that NH2-terminal GR 
fragments (1–488, 1–515, and 1–550) translocated to the 
nucleus, but not to the mitochondria (Fig. 6 A, lanes 2–4), 
indicating that these mutants contain NLS but not MLS. 
GR∆428-490 (∆DBD) and GR∆490-515 translocated to 
the mitochondria, but barely to the nucleus (Fig. 6 A, lanes 
5 and 6), indicating that NLS resides within aa 428–515 of 
hGR, which is in accordance with the three NLS described 
previously (31). GR∆550-600 translocated to the nucleus, 
but barely to the mitochondria (Fig. 6 A, lane 7), indicating 
that MLS resides, at least in part, within aa 550–600. A re-
sidual mitochondrial translocation observed with GR∆550-
600 suggests that the 550–600 domain may act in concert 
with another site within the COOH-terminal region of GR. 
Figure 5.  TEC induces mitochondrial, but not nuclear, transloca-
tion of GR in TEC-sensitive PD1.6 cells. PD1.6, PD1.6TEC−, and GR-
defi  cient PD1.6Dex− cells were incubated alone or with TEC for 4 h. 
Nonadherent lymphoma cells were harvested and subjected to subcel-
lular fractionation and Western blotting. The samples were harvested 
at an early stage after cocultivation with TEC, long before the onset 
of the apoptotic process. Thus, CytoC could be used as a marker for 
the mitochondria.JEM VOL. 203, January 23, 2006  195
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Similar to WT GR, the ∆727-777 mutant distributed to 
both the nucleus and the mitochondria (Fig. 6 A, lane 8). 
Also, the GR∆77-262 deletion mutant translocated to both 
the mitochondria and nucleus (unpublished data). Hence, 
NLS and MLS are located within diff  erent domains of the 
GR protein.
The 550–600 domain of GR comprises the α-Helix 3 (aa 
558–580) of the LBD. This α-helix is characterized by a se-
ries of positively charged aa (arginine/lysine), hydrophilic aa 
(threonine), and hydrophobic aa (valine, isoleucine, and leu-
cine), but lacks negatively charged aa. The positively charged 
and hydrophilic aa locate on the one side of the α-helix, 
whereas the hydrophobic aa locate on its other side (Fig. 6, B 
and C). This arrangement is compatible with the require-
ments for an MLS (32). It shows some sequence similarity 
to the MLS of cytochrome C oxidase (COX) (Fig. 6 D). To 
verify that the MLS resides within aa 558–580 stretch, Arg564 
and Arg575 of mouse GFP-GR (which correspond to hu-
man GRArg558 and Arg569, respectively) were each mu-
tated to glycine. Arg575 was also mutated to aspartate. The 
ability of these mutants to translocate to the mitochondria was 
compared with that of GFP-GR WT. R564G and R575G 
showed reduced ability to enter the mitochondria, whereas 
R575D behaved as WT in this respect (Fig. 6 E). These data 
indicate that the secondary structure created by R564 and 
R575, rather than their charge, is important for the MLS in-
tegrity. When this MLS is placed in the crystal structure of 
dimerized ligand-bound LBD, the two MLS appear adjacent 
(Fig. 6 F). The diff  erential location of MLS and NLS may 
explain the dissociated nuclear and mitochondrial transloca-
tions of GR observed in various cell types in response to di-
verse stimuli.
Figure 6.  (A) MLS and NLS are located within different domains 
of GR. GR-negative 293 epithelial cells were transfected with plasmids 
encoding the indicated human GR variants. After 20 h, the cells were 
subjected to subcellular fractionation and GR was detected on Western 
blot using the PA1-511 antibody to GR. (B) α-Helix wheel model of the 
putative MLS located within aa 558–580 of human GR. The positive-
charged arginine and lysine (red) and the hydrophilic threonine (orange) 
are located on the one side of the α-helix, whereas the hydrophobic aa 
leucine, isoleucine, valine, and tryptophane (blue) are located on the op-
posite side of the α-helix. Amino acids interacting with GC are labeled 
with gray numbers. This putative MLS is the α-Helix 3 of LBD. (C) The 
α-Helix 3 (aa 558–580) as it appears in the 1M2Z crystal structure. The 
same color labeling of aa is used as in B. (D) The MLS of GR resembles 
that of cytochrome C oxidase (COX). Amino acid sequence alignment be-
tween MLS of GR and MLS of COX. (E) The R564G and R575G mutants 
show reduced ability to enter the mitochondria. Mouse GFP-GR was 
point-mutated at aa 564 or 575 corresponding to the human R558 and 
R569, and the ability of these mutants to enter the mitochondria was 
determined as described in A. (F) The MLS (H3) of GR in the LBD crystal 
structure. The putative MLS is labeled in red in the 1M2Z crystal structure 
of a dimer complex of the human GR LBD (aa 521–777) bound to Dex and 
a Tif2 coactivator motif (reference 6).196  MITOCHONDRIAL GLUCOCORTICOID RECEPTOR AND APOPTOSIS | Sionov et al.
GR targeted to the mitochondria induces apoptosis
Our data suggest a role for mitochondrial GR in mediating 
apoptosis. To verify this hypothesis, we sought to distinguish 
between the eff  ects exerted by GR in the mitochondria and 
in other intracellular compartments. To this end, we con-
structed a GR variant (MLSCOX-GFP-GR) that exclusively 
localizes to the mitochondria. This variant was attained by 
adding the MLS of COX upstream to GFP-GR. We initially 
Figure 7.  (A and B) MLSCOX-GFP-GR is exclusively localized to the 
mitochondria. The mitochondria-directed GFP-GR variant was prepared 
by inserting the MLS of COX upstream to GFP-GR. HeLa cells (A), H1299 
(B), or PC-3 (B) cells were transfected with either GFP-GR or MLSCOX-GFP-
GR and stained with red mitrotracker to visualize the mitochondria be-
fore confocal microscopy. (C) MLSCOX-GFP-GR is more effi  cient in 
inducing apoptosis than GFP-GR. HeLa, L929 E8.2 A3, and PC-3 cells were 
transfected with plasmids encoding MLSCOX-GFP-GR or GFP-GR. After 
48 h, the percentage of apoptotic GFP-positive cells (transfectants) was 
compared with that of GFP-negative cells (nontransfectants) of the same 
sample. (D) NLS-defective GRK513-515A induces apoptosis of HeLa cells. 
Cells were transfected with plasmids encoding GFP-GRwt, GFP-GRK513-
515A, or pEGFP-F. After 48 h, the percentage of apoptotic cells was 
  determined as in C. (E and F) A nucleus-directed GFP-GR variant (NLSTAg-
GFP-GR) induces apoptosis of HeLa (E) and H1299 (F) cells. Cells were 
transfected with plasmids encoding GFP-GR, MLSCOX-GFP-GR, NLSTAg-
GFP-GR, or pEGFP-F. After 48 h, the percentage of apoptotic cells was 
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analyzed the intracellular localization of MLSCOX-GFP-GR 
in the absence or presence of Dex. HeLa, H1299, and PC3 
cells transfected with GFP-GR or MLSCOX-GFP-GR were 
either untreated or treated with 100 nM Dex for 2 h. There-
after, the cells were stained with red mitotracker to visualize 
the mitochondria and analyzed by confocal microscopy. The 
MLSCOX-GFP-GR exclusively localized to the mitochondria 
both in the absence and in the presence of Dex (Fig. 7, A and 
B). Hence, this construct was indeed useful for studying the 
eff  ect of mitochondrial GR on apoptosis. For this purpose, 
we transfected HeLa cervical carcinoma, PC-3 prostate ade-
nocarcinoma, and L929 E8.2 A3 fi  broblast-like cells with 
plasmids encoding either GFP-GR or MLSCOX-GFP-GR. 
After 48 h, the percentage of apoptotic transfectants was com-
pared with that of nontransfectants from the same sample. 
GFP-GR induced apoptosis of HeLa and L929 E8.2 A3 cells, 
but not of PC-3 cells (Fig. 7 C). MLSCOX-GFP-GR induced 
apoptosis of HeLa and L929 E8.2 A3 cells more effi   ciently 
than GFP-GR (Fig. 7 C). Interestingly, PC-3 cells, which do 
not undergo apoptosis by GFP-GR, were sensitive to 
MLSCOX-GFP-GR (Fig. 7 C). These results demonstrate that 
when GR is directed to the mitochondria, it is capable of in-
ducing apoptosis.
NLS-defective GR and a nuclear-directed GR possess 
proapoptotic properties
The aforementioned data indicate that mitochondrial GR 
triggers apoptosis induced by GC. We cannot, however, ex-
clude the possibility that GR may act at additional intracellu-
lar sites. To further study in which intracellular compartments 
GR may induce apoptosis, we analyzed the apoptotic ability 
of an NLS-defective GR mutant (pEGFP-ratGRK513-515A) 
and a nucleus-only directed GR variant (NLSTAg-GFP-GR). 
The latter was constructed by adding the NLS of SV40 T 
  antigen in triplet [(DPKKRKV)3] upstream to GFP-GR of 
mouse origin.
The apoptotic ability of pEGFP-GRK513-515A was 
compared with that of the parental pEGFP-GR WT in HeLa 
cells. It should be noted that pEGFP-GRK513-515A is un-
able to translocate to the nucleus (31). We observed that 
both GR WT and the NLS-defective GR variant induced 
apoptosis of HeLa cells (Fig. 7 D). pEGFP-F, used as a nega-
tive control, did not cause apoptosis of HeLa cells (Fig. 7 D). 
The ability of pEGFP-GRK513-515A to trigger apoptosis 
demonstrates that GR may mediate apoptosis by a nucleus-
independent manner.
Last, we compared the apoptotic ability of the nucleus-
directed NLSTAg-GFP-GR to those of MLSCOX-GFP-GR 
and parental GFP-GR. For this purpose, HeLa and H1299 
cells were transfected with the respective plasmids. Both 
NLSTAg-GFP-GR and MLSCOX-GFP-GR were more effi   -
cient than GFP-GR in inducing apoptosis of these cells (Fig. 
7, E and F). pEGFP-F did not induce apoptosis under the 
same circumstances (Fig. 7, E and F). These results suggest 
that an overexpressed GR may induce apoptosis when pres-
ent either in the mitochondria or in the nucleus. Under 
physiological conditions, we anticipate that the mitochon-
drial GR cooperates with nuclear GR in inducing apoptosis.
DISCUSSION
Numerous studies have been performed to elucidate the 
mechanisms by which GC induces apoptosis (2, 3, 5, 27). 
Several biochemical changes occurring immediately after ex-
posure to GC have been characterized. These include Ca2+ 
mobilization, activation of Src and Cdk2 kinases, and activa-
tion of phosphatidylinositol-specifi  c phospholipase C and 
acidic sphingomyelinase with subsequent ceramide generation 
(3, 33–35). Downstream eff  ector mechanisms of GC-induced 
apoptosis have also been defi  ned. These involve the mito-
chondria apoptotic pathway mediated by Bax, Bak, Bim, and 
tBid, and antagonized by Bcl-2 and Bcl-XL (3, 36). Dissipa-
tion of the mitochondrial membrane potential (∆Ψm ) is fol-
lowed by release of cytochrome C and Smac/Diablo to the 
cytosol (3, 36), which in turn leads to the activation of cas-
pase-9, caspase-3, and endonucleases (3, 36). With the good 
knowledge of downstream eff  ectors in GC-induced apopto-
sis, little is known about the role and fate of GR in this re-
sponse, as well as the reasons why some GR-expressing cells 
are sensitive, whereas others are not.
GR expression above a threshold level is necessary, but is 
not suffi   cient to activate GC-mediated apoptosis (2, 5, 27). 
Several studies have indicated that GC-resistant cells may 
  express similar GR levels as GC-sensitive cells (2, 37–39). 
Likewise, in the present study, we show that GC-sensitive 
(PD1.6, 2B4, thymocytes) and some GC-resistant (B10, S49) 
cells express high GR levels. These observations suggest that 
the apoptotic response is regulated by additional factors act-
ing downstream to ligand–receptor interaction. One possi-
bility is that only a certain isotype of GR can initiate apoptosis. 
Indeed, various mRNA transcripts of GR have been ob-
served in both mouse and human cells (19, 40, 41); among 
them, the 1A variant is most abundantly expressed in hema-
topoietic cells (19, 20). The 1A transcript is mainly translated 
to a  90-kD GR and a small proportion of a higher molecu-
lar mass GR ( 150 kD) (18). The various cells analyzed in 
our study mainly express the  90-kD form corresponding to 
GRα. We also detected a small amount of  150-kD GR in 
the cytosolic fraction of PD1.6, 2B4, B10, and S49 cells (un-
published data). Hence, the  150-kD GR form is not ex-
pressed exclusively in cells sensitive to GC, but in GC-resistant 
cells as well.
Another factor that could aff  ect GC-mediated apoptosis is 
the intracellular traffi   cking of GR. GC causes nuclear trans-
location of GR in both GC-sensitive and GC-resistant cells. 
Both transactivation-defi   cient and transrepression-defi  cient 
GR variants have been shown to restore GC sensitivity in 
human T-ALL cells (7, 14, 42, 43). These data together with 
our present fi  nding that an NLS-defi  cient GR mutant is pro-
apoptotic suggest that nuclear-independent mechanisms are 
likely involved in this death pathway.
It has been suggested that mGR is involved in GC-induced 
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full-length 1A transcript, imparted both mGR expression 
and GC sensitivity to some GC-resistant cells (18). How-
ever, this cDNA also caused GR overexpression in the cy-
tosol (18), which may have contributed to the GC sensitivity 
of the cells. In the present paper, we have further studied 
the role of mGR in GC-induced apoptosis by analyzing 
mGR expression in GC-sensitive and resistant lymphoid 
cells. mGR was expressed on some cell types that were 
GC resistant, but not on the GC-sensitive cells studied. 
Thus, mGR is not required for GC-induced apoptosis, 
and its mere presence does not impose susceptibility to 
GC. Our fi  ndings are compatible with those of Gametchu 
et al. (17), showing that mGR-negative lymphoma cells 
may be GC sensitive.
Another possibility could be that mitochondrial GR is 
the trigger of apoptosis. GR has been shown to be located 
within the mitochondria in some cell types (22–24). In these 
studies, GR was detected in the mitochondrial membranes 
and in the matrix space. Likewise, we also observed a basal 
mitochondrial GR expression in most of the lymphoma cells 
analyzed. However, Dex induces GR translocation to the 
mitochondria in GC-sensitive, but not in GC-resistant, cells. 
This is in contrast with nuclear translocation of GR that takes 
place in all cell types. This is the fi  rst qualitative diff  erence in 
GR behavior described that distinguishes between GC-sensi-
tive and resistant cells, suggesting a role for mitochondrial 
GR in apoptosis.
In GC-sensitive cells, mitochondrial and nuclear translo-
cations of GR occur simultaneously within the fi  rst minutes 
after exposure to Dex. After its initial translocation, the 
amount of GR in the mitochondria was maintained at a 
steady state. Thus, the elevated mitochondrial GR level is 
sustained in GC-sensitive cells, which is in contrast with the 
transient residence of GR in the mitochondria (5–30 min) in 
HeLa cells and with the reduced amount of mitochondrial 
GR in a glioma cell line after Dex treatment (24, 44). The 
sustained expression of GR in the mitochondria of GC-sen-
sitive cells may account for the apoptotic eff  ects of GC. An-
other support for a role of mitochondrial GR in mediating 
apoptosis comes from the observation that TECs, which trig-
ger apoptosis of PD1.6 in a GR-dependent manner (30), in-
duces GR translocation to the mitochondria, but not to the 
nucleus. Thus, GR translocation to the nucleus is not neces-
sary for the apoptotic response. However, we cannot exclude 
the possibility that mitochondrial GR cooperates with nu-
clear GR in inducing apoptosis. The fact that a mitochon-
dria-directed GR induces apoptosis suggests that exclusive 
expression of GR in the mitochondria is suffi   cient for trig-
gering apoptosis. Conversely, a nucleus-directed GR is also 
proapoptotic. It should be noted that the latter data were ob-
tained by a transient transfection assay where the proteins 
were overexpressed. Thus, the GR eff  ects are more pro-
nounced than at physiological GR levels. Nevertheless, it is a 
valuable approach that provides information on GR func-
tion. Altogether, our data show that mitochondrial transloca-
tion of GR correlates with apoptotic sensitivity.
This behavior of GR resembles that of the proapoptotic 
p53 and Nur77 proteins. These proteins have recently been 
shown to have a direct apoptogenic role at the mitochondria, 
besides their nuclear eff  ects (45, 46). Our results add GR to 
the growing list of proteins that mediate apoptosis when lo-
calized to the mitochondria. Also, the thyroid, estrogen β 
and retinoid X receptors have been shown to be located in 
the mitochondria (24, 47, 48). Thus far, however, the mito-
chondrial localization of these receptors has not been impli-
cated in apoptosis.
The mechanism by which mitochondrial GR mediates 
apoptosis is a matter for further study. GC has been shown to 
regulate mitochondrial transcription and energy production 
(24), and GRE elements have been found in the mitochon-
drial genome (49). It should be mentioned in this regard that 
some of the apoptotic eff  ects of p53 and Nur77 occur inde-
pendently of their transcriptional activities (45, 46). p53 and 
Nur77 interact with the protective Bcl-XL and Bcl-2 proteins 
in the mitochondria (46, 50). It would, therefore, be interest-
ing to fi  nd out whether mitochondrial GR has similar eff  ects.
Another important fi  nding of our study is that nuclear and 
mitochondrial GR translocations are diff  erentially regulated. 
For instance, Dex induces both mitochondrial and nuclear 
GR translocations in GC-sensitive lymphoid cells, but only 
nuclear translocation in GC-resistant cells. In contrast, TEC 
induces mitochondrial, but not nuclear, GR translocation. 
Furthermore, we have partially characterized a putative MLS 
comprising the α-Helix 3 (aa 558–580) of LBD. This domain 
lies COOH terminally to the three NLSs (aa 428–515) (31), 
and possesses several traits of an MLS (32). The hydrophobic 
and positively charged residues are partitioned on opposite 
sides of the helix. Most of the proteins destined to the mito-
chondria contain an NH2-terminal mitochondrial transfer 
peptide that is cleaved off   after entering the mitochondrial ma-
trix (32). Some mitochondrial proteins, however, have a non-
cleavable internal MLS (32). The GR detected by us in the 
mitochondria is of a similar size as cytosolic GR, indicating that 
it does not undergo cleavage upon mitochondrial  translocation. 
Hence, GR contains a noncleavable internal mitochon  drial 
targeting sequence possessing an amphipathic presequence-
type helix. This target sequence resembles the internal MLS 
of BCS1 (51).
It is conceivable that GR is transported to the mitochon-
dria by a heat-shock protein, as its 558–580 domain overlaps 
with one of several characterized Hsp90-binding sites (5), 
and both Hsp90 and Hsp70 function as chaperones that inter-
act with the mitochondrial protein import receptor Tom 70 
(52). Further studies are required to verify the role of heat 
shock proteins in GR traffi   cking.
In summary, we conclude that mitochondrial GR acts 
independently of nuclear GR in inducing apoptosis, and that 
mitochondrial and nuclear GR translocations are diff  eren-
tially regulated. Given the multiple nuclear adverse eff  ects of 
GC therapy, our fi  ndings propose further research focusing 
on the development of therapeutic modalities that preferen-
tially direct GR to the mitochondria.JEM VOL. 203, January 23, 2006  199
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MATERIALS AND METHODS
Cells. PD1.6 thymic lymphoma (30), B10 thymic lymphoma (30), S49 T 
lymphoma (provided by J. Hochman, The Hebrew University of Jerusalem, 
Jerusalem, Israel), TEC (provided by A. Kruisbeek, The Netherlands Cancer 
Institute, Amsterdam, Netherlands), 293 kidney epithelial cells, HeLa cervi-
cal carcinoma, and L929 E8.2 A3 fi  broblast-like cells (provided by W.V. 
Vedeckis, Louisiana State University, New Orleans, LA) were grown in 
DMEM supplemented with 10% heat-inactivated FCS, 2 mM glutamine, 10 
mM Hepes, 1 mM sodium pyruvate, nonessential aa, antibiotics, and 50 μM 
β-mercaptoethanol. 2B4 T cell hybridoma, 4B2 PML, Jurkat ALL, thymo-
cytes, H1299 lung adenocarcinoma, and PC-3 prostate adenocarcinoma 
were cultured in RPMI 1640 with the same supplements as for DMEM. 
PD1.6Dex− cells were derived from PD1.6 cells by repeated exposure to in-
creasing concentrations of Dex and PD1.6TEC− cells were derived from 
PD1.6 cells repeatedly cocultured with TECs (30).
Plasmids. The following plasmids were used: GFP-mouse GR (provided 
by L.J. Muglia, Washington University in St. Louis, St. Louis, MO); 
hGR∆DBD and hGR∆77-262 (provided by W. Doppler, Universität 
  Innsbruck, Innsbruck, Austria); hGR WT, hGR1-488, hGR1-515, hGR1-
550, hGR418-777, hGR∆490-515, hGR∆550-600, hGR550-777, and 
hGR∆727-777 (provided by T.D. Gelehrter, University of Michigan, Ann 
Arbor, MI); pEGFP-rat GR and pEGFP-ratGR K513-515A (provided by 
K.R. Yamamoto, University of California, San Francisco, CA); pCMV/
myc/mito (Invitrogen) (provided by S. Ostrand-Rosenberg, University of 
Maryland, Baltimore, MD); pCMV/myc/nuc (Invitrogen) (provided by 
D. Bensi, Mayo Clinic, Rochester, MN); farnesylated GFP (pEGFP-F; 
CLONTECH) and pEGFP-N1 (CLONTECH) (provided by Y. Haupt, 
The Hebrew University of Jerusalem, Jerusalem, Israel). A mitochondria-di-
rected GFP-GR variant (MLSCOX-GFP-GR) was prepared by inserting the 
MLS of COX (M  S  V  L  T  P  L  L  L  R  G  L  T  G  S  A  R  R  L  P  V  P  R  A  K  I  H  S  L  ) NH2-termi-
nal to GFP-GR. A PCR product containing this MLS was obtained from 
pCMV/myc/mito using 5′-primer C  T  A  G  C  T  A  G  C  T  G  A  C  G  C  A  A  A  T  G  G  G-
C  G  G  T  A  G  G  C  G  T  G  -3′ harboring a NheI site and 3′-primer C  C  C  A  C  C  G  G-
T  T  T  G  G  C  C  C  C  A  T  T  C  A  G  A  T  C  C  T  C  T  T  C  -5′ harboring a AgeI site. After 
double digestion with NheI and AgeI, the PCR product was inserted within 
the NheI/AgeI sites of GFP-GR. A nucleus-directed GFP-GR variant (NL-
STAg-GFP-GR) was prepared by inserting the NLS of SV40 T antigen in 
triplet ([DPKKRKV)3]) NH2-terminal to GFP-GR. pCMV/myc/nuc was 
used as template for the aforementioned primers. Mutations in GR were in-
troduced by site-directed mutagenesis (QuickChange kit; Stratagene). Se-
quencing of plasmids was done at the DNA Sequencing Facility of The 
Hebrew University of Jerusalem, Israel.
Indirect immunofl  uorescence. Cell surface staining of GR was per-
formed by incubating cells with M20 antibody to GR (Santa Cruz Biotech-
nology) followed by FITC-conjugated Affi   niPure F(ab)2-fragment of goat 
anti–rabbit IgG (Jackson ImmunoResearch Laboratories). Intracellular GR 
staining was performed on rehydrated methanol-fi  xed cells.
Determination of apoptosis. Apoptosis was assessed by cell cycle analysis 
and caspase 3 activation. For cell cycle distribution, cells were fi  xed with 
ice-cold methanol, rehydrated in PBS, and treated with 50 μg/ml RNase. 
After adding 5 μg/ml propidium iodide, the DNA content was analyzed 
by fl  ow cytometry (FACSCalibur; Becton Dickinson). Subdiploid cells are 
regarded as apoptotic cells, and presented as percentage of the whole cell 
population. Caspase 3 activation was analyzed by incubating rehydrated 
methanol-fi  xed cells with antibody to cleaved caspase 3 (Asp 175; Cell Sig-
naling Technologies) followed by FITC-conjugated Affi   niPure F(ab)2-frag-
ment of goat anti–rabbit IgG (Jackson ImmunoResearch Laboratories).
Subcellular fractionation and Western blot. Cell pellets were gently 
resuspended in cytoplasmic buff  er (10 mM Hepes, pH 7.4; 1.5 mM MgCl2, 
10 mM KCl, 0.5 mM DTT, 10 mM Na2MoO4, 2 mM PMSF, 20 μg/ml 
aprotinin, 0.1% NP-40; 25 mM NaF, and 0.2 mM Na3VO4) and kept on 
ice for 10 min before centrifugation at 900 g for 10 min. The nuclear pellets 
were processed as described below. The cytoplasmic supernatant was re-
centrifuged at 900 g to ensure complete removal of nuclear material. The 
resulting supernatant was centrifuged at 10,000 g for 30 min. The cytosolic 
supernatant was processed for Western blot by adding protein sample buff  er 
(PSB) × 4.5. The mitochondrial pellet was washed with cytoplasmic buf-
fer, recentrifuged at 10,000 g, and dissolved in PSB × 1.5. The nuclear pel-
let was washed with cytoplasmic buff  er and recentrifuged at 900 g before 
their extraction in nuclear buff  er (20 mM Hepes, pH 7.4, 1.5 mM MgCl2, 
420 mM NaCl, 25% glycerol (vol/vol), 0.2 mM EDTA, 0.5 mM DTT, 
10 mM Na2MoO4, 2 mM PMSF, 20 μg/ml aprotinin, 25 mM NaF, and 
0.2 mM Na3VO4). The nuclear extracts were cleared at 20,000 g for 10 min, 
and processed for Western blot by adding PSB × 4.5. GR was detected 
on Western blot by using the PA1-511A (Affi   nity BioReagent), M20, or 
P20 antibodies to GR (Santa Cruz Biotechnology). The blots were re-
probed with antibodies to α-tubulin (Sigma-Aldrich), cytochrome C (Cy-
toC; Santa Cruz Biotechnology), VDAC (Oncogene Research Products), 
or histone H2B (LG2-2; provided by M. Monestier, Temple University, 
Philadelphia, PA) (53). The Oncogene cytosol/mitochondria fractionation 
kit (QIA88; Oncogene Research Products) was used according to the man-
ufacturer’s instructions.
Cocultivation of PD1.6 cells with TECs. 5 × 106 TECs were seeded in 
75 cm2 tissue culture bottles (Nunc). On the following day, 107 PD1.6 cells 
were added to the TEC monolayer in a 40-ml medium. After 4 h, nonad-
herent PD1.6 cells were harvested and processed for cell fractionation as de-
scribed before.
Transient transfection assay. Cells were transfected with the given plas-
mids by using the calcium phosphate precipitation method. For apoptosis as-
say, the adherent cells were trypsinized and collected in culture supernatants. 
Flow cytometry was performed while gating on GFP positive or negative 
cells. Percentage of apoptotic transfectants (GFP-positive) was compared 
with that of nontransfectants (GFP-negative) from the same culture. For 
confocal microscopy, the cells were incubated with red mitotracker (50 nM; 
Invitrogen) during the last 30 min of incubation. For cell fractionation stud-
ies, adherent transfected cells were harvested with rubber policeman and 
centrifuged at 720 g for 5 min.
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